Clinical Catch-Up: January 18-22 | BioSpace
The Pharma Data
JANUARY 24, 2021
Brilacidin has shown in vitro to be have antiviral properties against different SARS-CoV-2 strains and other human coronaviruses. All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo. Read on to see. COVID-19-Related. It also has robust antimicrobial properties.
52 
Let's personalize your content